Sign in
REGN-REGENERON PHARMACEUTICALS INC

Regeneron Reports Strong Q4 Earnings and Announces New Dividend Amid Lawsuit Against Sanofi Over Dupixent Data Access

Wednesday

19 February, 2025

Regeneron Pharmaceuticals has reported a remarkable Q4, with earnings surpassing expectations and a significant revenue boost driven by Dupixent and Eylea. As the company navigates a lawsuit against Sanofi, can its strong financial performance and promising pipeline sustain investor confidence amidst these challenges?

article image for REGN

Article Impact Score

0
50
100
Under­perform
Bear­ish
Neu­tral
Bull­ish
Out­perform
70
Key Takeaways
  • Regeneron has demonstrated strong financial results, with Q4 earnings surpassing expectations and a notable 10% revenue increase.
  • Dupixent's substantial sales figures for 2024 underscore its importance in managing chronic illnesses, paving the way for future expansion.
  • The FDA's Priority Review for Dupixent indicates opportunities for entering new markets.
  • An upgrade from Leerink to Outperform signals optimism regarding Regeneron's future value despite current stock challenges.
  • Ongoing legal matters with Sanofi highlight the high stakes and potential for growth as clinical advancements progress.
More on REGENERON PHARMACEUTICALS INC
Read more insights on REGENERON PHARMACEUTICALS INC

Most Read

Join Foliko Premium!

Unlock the entire library of Foliko's Generative AI Investment Research. Plus, get AI powered trading signals and stock price predictions.

Go Premium - 7 Day Free Trial
home-footer-logo

Any content provided on our website is for information purposes only. We do not provide investment advice, nor do we consider ourselves a financial institution. Seek a duly licensed professional for investment advice.